Recurrent Deep Vein Thrombosis (DVT) with Negative D-Dimer in a Patient on Rivaroxaban: A Diagnostic Pitfall

Abstract

We present a case of a 60-year-old female with a history of recurrent venous thromboembolism (VTE), who re-presented with right leg pain and was found to have a non-occlusive deep vein thrombosis (DVT) in the common femoral vein (CFV) despite being on rivaroxaban. Notably, the D-dimer was negative, and the Wells score was one. Duplex ultrasound confirmed non-compressibility of the CFV and femoral vein (FV). This case emphasizes the limitation of D-dimer testing in patients on direct oral anticoagulants (DOACs) and the importance of considering imaging even in low pre-test probability cases when clinical suspicion persists.

Share and Cite:

Chaplin, J. , Akhtari, A. and Lum, W. (2025) Recurrent Deep Vein Thrombosis (DVT) with Negative D-Dimer in a Patient on Rivaroxaban: A Diagnostic Pitfall. Open Journal of Emergency Medicine, 13, 285-289. doi: 10.4236/ojem.2025.134025.

1. Introduction

D-dimer is widely used to exclude VTE in low-risk patients, especially when combined with pre-test probability tools such as the Wells score [1] [2]. Current international guidelines recommend excluding DVT without imaging when the D-dimer is negative, and the Wells score is low [2] [3]. However, this strategy has not been validated in patients already receiving therapeutic anticoagulation. In such cases, D-dimer levels may be artificially low, leading to false reassurance [4]. This case illustrates a diagnostic challenge in such a context and highlights the need for cautious interpretation of algorithms in anticoagulated patients.

2. Case Presentation

2.1. Patient

A 60-year-old female presented to the Emergency Department (ED) with a 24-hour history of medial right thigh pain radiating to the anterior thigh. The pain had spontaneously improved and she was not using analgesia at the time of review. She denied any recent surgery, trauma, immobilization, travel, or malignancy.

The patient reported taking her last dose of rivaroxaban approximately 6 hours prior to presentation. An anti-Xa level specific to rivaroxaban was not performed due to unavailability in our ED at the time.

2.2. Past Medical History

  • Four prior episodes of right lower limb DVT.

  • Pulmonary embolism 29 years ago.

  • Recent switch from warfarin to rivaroxaban 20 mg daily (3 weeks prior to presentation).

2.3. Examination

  • Vitals: Normal.

  • No limb swelling.

  • Mild tenderness in the right anterior thigh.

  • Full range of motion preserved.

2.4. Investigations

  • Full blood count and biochemistry unremarkable.

  • D-dimer: 0.3 µg/mL (within normal range).

  • Wells score: 1 for previous documented DVT.

2.5. Initial Management

Given that the D-dimer was negative and patient’s pain was settled and patient was on therapeutic dose of rivaroxaban with a reasonable compliance after discussion with the patient, she was discharged with clear instructions to book an appointment with her GP in 48 hours to review and arrange a Doppler ultrasound if indicated. Pt called her GP to make an appointment which the GP was concerned by the patient’s history requested a lower limb ultrasound to be done before departure from ED.

3. Imaging Findings

The ultrasound team noted differences in echogenicity and vein compressibility, distinguishing chronic post-thrombotic changes (seen in the femoral and gastrocnemius veins) from the new thrombus in the CFV. The representative images are shown in Figure 1 and Figure 2. The presence of a newly non-compressible segment with different characteristics supported the diagnosis of an acute non-occlusive thrombus. The sonographic findings are summarized in Table 1.

Figure 1. Ultrasound image showing vein compressibility assessment.

Figure 2. Duplex ultrasound demonstrating venous compressibility and partial thrombus in CFV.

Table 1. Ultrasound vein findings.

Vein

Findings

Common Femoral Vein (CFV)

Non-occlusive DVT, non-compressible

Femoral Vein (FV)

Non-compressible from 10 cm above the knee

Popliteal Vein (POPV)

Compressible, no thrombus

Tibio-Peroneal Trunk

Compressible, normal flow

Posterior Tibial Vein

Patent

Peroneal Vein

Patent

Medial Gastrocnemius Vein

Patent, likely chronic changes

Duplex imaging revealed a non-occlusive thrombus in the right common femoral vein, extending into the femoral vein approximately 10 cm above the knee. The popliteal and calf veins were clear.

In response to these findings, warfarin was initiated alongside the current dose of rivaroxaban. An INR was requested for 48 hours later, with a plan to discontinue rivaroxaban once the INR reached the therapeutic range of 2 to 3, in accordance with clinical guidelines [3].

4. Discussion

This case reveals a diagnostic trap: low Wells score and negative D-dimer provided false reassurance in a patient at high risk for recurrent VTE. DOACs, particularly rivaroxaban, suppress thrombin and fibrin formation, potentially lowering D-dimer levels even in the presence of thrombosis [4].

Multiple studies have shown reduced D-dimer reliability in patients on rivaroxaban. Mohamed et al. demonstrated significantly reduced D-dimer levels in patients on rivaroxaban [4]. Wu et al. reported poor predictive value of D-dimer post-surgery in patients on rivaroxaban [5].

Our patient’s negative D-dimer (0.3 µg/mL) and Wells score of 1 would typically preclude further testing. However, her history of recurrent DVTs and recent medication change warranted a more cautious approach. Clinical judgment prevailed when her GP requested imaging, which confirmed the diagnosis.

This case echoes reports from Alsararatee and Ahmed et al., where VTE was diagnosed despite negative D-dimer while on rivaroxaban [6] [7]. Comparable evidence has been documented in earlier studies [8] [9]. The findings stress the limitations of current algorithms in anticoagulated patients.

5. Conclusions

This case also reminds us that even as senior ED specialists; we often trust guideline-based approaches such as Wells scoring and D-dimer testing. However, relying solely on these tools without considering the clinical context may lead to inappropriate conclusions. Therefore, we strongly advocate for a patient-centered approach that is informed by clinical judgment, individual patient history, and practical experience, especially in complex or high-risk cases.

Clinicians must recognize that D-dimer assays may be falsely negative in patients on rivaroxaban. In those with significant thromboembolic history, persistent symptoms should prompt imaging, even with low pre-test probability. Clinical acumen remains paramount in the assessment of VTE risk in anticoagulated patients.

Acknowledgements

Patient Consent: Written informed consent was obtained from the patient for publication of this case report and accompanying images.

We would like to thank Dr Sharna Bennett, the patient’s general practitioner, for her crucial role in early imaging referral and clinical coordination.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

[1] Bounameaux, H., Cirafici, P., de Moerloose, P., Schneider, P., Slosman, D., Reber, G., et al. (1991) Measurement of D-Dimer in Plasma as Diagnostic Aid in Suspected Pulmonary Embolism. The Lancet, 337, 196-200.[CrossRef] [PubMed]
[2] Wells, P.S., Anderson, D.R., Rodger, M., Forgie, M., Kearon, C., Dreyer, J., et al. (2003) Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein Thrombosis. New England Journal of Medicine, 349, 1227-1235.[CrossRef] [PubMed]
[3] NICE (2012) Rivaroxaban for the Treatment of Deep Vein Thrombosis and Prevention of Recurrent Deep Vein Thrombosis and Pulmonary Embolism. National Institute for Health and Care Excellence (NICE), National Appraisal Guidance.
[4] Mohamad, H., Fronas, S.G., Jørgensen, C.T., Tavoly, M., Garabet, L. and Ghanima, W. (2022) The Effect of Rivaroxaban on the Diagnostic Value of D-Dimer in Patients with Suspected Deep Vein Thrombosis. Thrombosis Research, 216, 22-24.[CrossRef] [PubMed]
[5] Wu, C.-T., Chen, B., Wang, J.-W., Yen, S.-H. and Huang, C.-C. (2018) Plasma D-Dimer Is Not Useful in the Prediction of Deep Vein Thrombosis after Total Knee Arthroplasty in Patients Using Rivaroxaban for Thromboprophylaxis. Journal of Orthopaedic Surgery and Research, 13, Article No. 173.[CrossRef] [PubMed]
[6] Alsararatee, H.H. (2025) Novel Insights into Pulmonary Embolism with Negative D-Dimer Results. BMJ Case Reports, 18, e264995.[CrossRef] [PubMed]
[7] Said Ahmed, T., Tewari, P., Kaur, J., Rizvi, S. and Nafsi, T. (2016) Recurrence of Pulmonary Embolism While on Rivaroxaban: Treatment Failure. Chest, 149, A505.[CrossRef]
[8] Jennings, S.T., Manh, K.N.P. and Bita, J. (2019) Morbidly Obese Patient on Rivaroxaban Presents with Recurrent Upper Extremity Deep Vein Thrombosis: A Case Report. Journal of Pharmacy Practice, 33, 712-719.[CrossRef] [PubMed]
[9] Hatfield, L. (2017) Recurrent VTE Despite Anticoagulation. Emergency Physicians Monthly.

Copyright © 2026 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.